Progress in drug development has steadily improved survival from childhood malignant tumors over the past decades, but there is still a tremendous need for safe and effective drugs with which to treat pediatric cancers. Between 10% and 30% of children with cancer die within 5 years of diagnosis.1 Secondary tumors and treatment-related toxic effects, such as cognitive and endocrine dysfunctions, are also common among young survivors.